ICOSAVAX INC (ICVX)

Company Profile

Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. The company is headquartered in Seattle, Washington and currently employs 60 full-time employees. The company went IPO on 2021-07-29. The firm uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on life-threatening respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens. Its pipeline includes vaccine candidates targeting viral causes of pneumonia. The company is developing these candidates for older adults, a patient population with high unmet need. Its lead vaccine candidate, IVX-A12, is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). The company is also developing additional vaccine candidates as part of its strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults, including influenza and SARS-CoV-2.

Company Info

ICOSAVAX INC

1930 Boren Ave., Suite 1000

Seattle WASHINGTON

P: 12067370085

CEO: Adam Simpson

Employees: 60

Website: https://icosavax.com/